A Dual Concentration-Tailored Cytokine-Chemo Nanosystem to Alleviate Multidrug Resistance and Redirect Balance of Cancer Proliferation and Apoptosis

References

• Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120:6–15. doi:10.1038/s41416-018-0328-y
   PubMed Web of Science ®Google Scholar
• Young PA, Morrison SL, Timmerman JM. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol. 2014;41:623–636. doi:10.1053/j.seminoncol.2014.08.002
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Antibody–cytokine fusion proteins. Arch Biochem Biophys. 2012;526:194–205. doi:10.1016/j.abb.2012.03.001
   PubMed Web of Science ®Google Scholar
• Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFα; stabilizes tumor vessels and enhances active immunotherapy. PNAS. 2012;109:7841–7846. doi:10.1073/pnas.1118296109
   PubMed Web of Science ®Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today. 2012;17:583–590. doi:10.1016/j.drudis.2012.01.007
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010;6:1952–1967. doi:10.1002/smll.200901789
   PubMed Web of Science ®Google Scholar
• Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66:1403–1408. doi:10.1016/S0006-2952(03)00490-8
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65. doi:10.1038/sj.cdd.4401189
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305–1308. doi:10.1126/science.281.5381.1305
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397
   PubMed Web of Science ®Google Scholar
• Boland K, Flanagan L, Prehn J. Paracrine control of tissue regeneration and cell proliferation by Caspase-3. Cell Death Dis. 2013;4:e725. doi:10.1038/cddis.2013.250
   PubMed Web of Science ®Google Scholar
• Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942–1951. doi:10.1200/JCO.1987.5.12.1942
   PubMed Web of Science ®Google Scholar
• Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1989;7:298–303. doi:10.1200/JCO.1989.7.3.298
   PubMed Web of Science ®Google Scholar
• Kedar E, Palgi O, Golod G, Babai I, Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother. 1997;20:180–193. doi:10.1097/00002371-199705000-00003
   PubMed Web of Science ®Google Scholar
• van der Veen AH, Eggermont AMM, Seynhaeve ALB, van Tiel ST, ten Hagen TLM. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-α in soft tissue sarcoma bearing rats. Int J Cancer. 1998;77:901–906. doi:10.1002/(SICI)1097-0215(19980911)77:6
   PubMed Web of Science ®Google Scholar
• Shenoi MM, Iltis I, Choi J, et al. Nanoparticle Delivered Vascular Disrupting Agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013;10:1683–1694. doi:10.1021/mp300505w
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010;16:6139–6149. doi:10.1158/1078-0432.CCR-10-0978
   PubMed Web of Science ®Google Scholar
• Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11:169–183. doi:10.1080/10717540490433895
   PubMed Web of Science ®Google Scholar
• Shao J, Griffin RJ, Galanzha EI, et al. Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep. 2013;3:1293. doi:10.1038/srep01293
   PubMed Web of Science ®Google Scholar
• Xu G, Gu H, Hu B, et al. PEG-b-(PELG-g-PLL) nanoparticles as TNF-α nanocarriers: potential cerebral ischemia/reperfusion injury therapeutic applications. Int J Nanomed. 2017;12:2243–2254. doi:10.2147/IJN.S130842
   PubMed Web of Science ®Google Scholar
• Lee C-H, Cheng S-H, Wang Y-J, et al. Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution. Adv Funct Mater. 2009;19:215–222. doi:10.1002/adfm.200800753
   Web of Science ®Google Scholar
• Chen NT, Souris JS, Cheng SH, et al. Lectin-functionalized mesoporous silica nanoparticles for endoscopic detection of premalignant colonic lesions. Nanomedicine. 2017;13:1941–1952. doi:10.1016/j.nano.2017.03.014
   PubMed Web of Science ®Google Scholar
• Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Varnamkhasti BS, Saboury AA. Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Bio Pharmacot. 2019;109:1100–1111. doi:10.1016/j.biopha.2018.10.167
   Google Scholar
• Lee C-H, Cheng S-H, Huang I-P, et al. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed. 2010;49:8214–8219. doi:10.1002/anie.201002639
   PubMed Web of Science ®Google Scholar
• Zhou Y, Quan G, Wu Q, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018;8:165–177. doi:10.1016/j.apsb.2018.01.007
   PubMed Web of Science ®Google Scholar
• Cheng S-H, Lee C-H, Chen M-C, et al. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics—the trio of imaging, targeting and therapy. J Mater Chem. 2010;20:6149–6157. doi:10.1039/c0jm00645a
   Web of Science ®Google Scholar
• Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6:1794–1805. doi:10.1002/smll.201000538
   PubMed Web of Science ®Google Scholar
• Tsai C-P, Chen C-Y, Hung Y, Chang F-H, Mou C-Y. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J Mater Chem. 2009;19:5737–5743. doi:10.1039/B905158A
   Web of Science ®Google Scholar
• Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol. 1986;103:755–766. doi:10.1083/jcb.103.3.755
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322. doi:10.1002/(SICI)1097-4652(200003)182:3
   PubMed Web of Science ®Google Scholar
• Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res Lett. 2018;13:339. doi:10.1186/s11671-018-2728-6
   PubMed Web of Science ®Google Scholar
• Haddick L, Zhang W, Reinhard S, et al. Particle-size-dependent delivery of antitumoral miRNA using targeted mesoporous silica nanoparticles. Pharmaceutics. 2020;12(6):505. doi:10.3390/pharmaceutics12060505
   PubMed Web of Science ®Google Scholar
• Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000;3:234–258.
   PubMed Web of Science ®Google Scholar
• Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134:2139–2147. doi:10.1021/ja2084338
   PubMed Web of Science ®Google Scholar
• Huang I-P, Sun S-P, Cheng S-H, et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein–mediated drug resistance. Mol Cancer Ther. 2011;10:761–769. doi:10.1158/1535-7163.MCT-10-0884
   PubMed Web of Science ®Google Scholar
• Igaz N, Bélteky P, Kovács D, et al. Functionalized mesoporous silica nanoparticles for drug-delivery to multidrug-resistant cancer cells. Int J Nanomed. 2022;17:3079–3096. doi:10.2147/IJN.S363952
   PubMed Web of Science ®Google Scholar
• Yang X, Li M, Liang JI, Hou XY, He XX, Wang KM. NIR-controlled treatment of multidrug-resistant tumor cells by mesoporous silica capsules containing gold nanorods and doxorubicin. ACS Appl Mater Interfaces. 2021;13(13):14894–14910. doi:10.1021/acsami.0c23073
   PubMed Web of Science ®Google Scholar
• Takada H, Chen NJ, Mirtsos C, et al. Role of SODD in regulation of tumor necrosis factor responses. Mol Cell Biol. 2003;23:4026–4033. doi:10.1128/MCB.23.11.4026-4033.2003
   PubMed Web of Science ®Google Scholar
• MacEwan DJ. TNF ligands and receptors--a matter of life and death. Br J Pharmacol. 2002;135:855–875. doi:10.1038/sj.bjp.0704549
   PubMed Web of Science ®Google Scholar
• Walther W, Kobelt D, Bauer L, Aumann J, Stein U. Chemosensitization by diverging modulation by short-term and long-term TNF-α action on ABCB1 expression and NF-κB signaling in colon cancer. Int J Oncol. 2015;47(6):2276–2285. doi:10.3892/ijo.2015.3189
   PubMed Web of Science ®Google Scholar
• Bu H, Gao Y, Li Y. Overcoming multidrug resistance (MDR) in cancer by nanotechnology. Sci China Chem. 2010;53:2226–2232. doi:10.1007/s11426-010-4142-5
   Web of Science ®Google Scholar
• Meng H, Liong M, Xia T. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS nano. 2010;4(8):4539–4550. doi:10.1021/nn100690m
   PubMed Web of Science ®Google Scholar
• Meng H, Mai W, Zhang H. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS nano. 2013;7(2):994–1005. doi:10.1021/nn3044066
   PubMed Web of Science ®Google Scholar
• Wang D, Xu X, Zhang K. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int J Nanomed. 2018;13:187–198. doi:10.2147/IJN.S150610
   PubMed Web of Science ®Google Scholar
• Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale. 2011;3:4314–4322. doi:10.1039/C1NR10580A
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255–260. doi:10.1016/S0955-0674(99)80034-9
   PubMed Web of Science ®Google Scholar
• Koonce N, Quick C, Hardee M, et al. Combination of gold nanoparticle-conjugated tumor necrosis factor-α and radiation therapy results in a synergistic antitumor response in murine carcinoma models. IJROBP. 2015;93:588–596. doi:10.1016/j.ijrobp.2015.07.2275
   Google Scholar
• Corti A, Sacchi A, Gasparri AM, et al. Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. J Nanobiotechnol. 2021;19:128. doi:10.1186/s12951-021-00871-y
   PubMed Web of Science ®Google Scholar
• Evans ER, Bugga P, Asthana V, Drezek R. Metallic nanoparticles for cancer immunotherapy. Mater Today. 2018;21:673–685. doi:10.1016/j.mattod.2017.11.022
   Web of Science ®Google Scholar
• Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci. 2004;117:5197–5208. doi:10.1242/jcs.01483
   PubMed Web of Science ®Google Scholar
• Wang X-H, Hong X, Zhu L, et al. Tumor necrosis factor alpha promotes the proliferation of human nucleus pulposus cells via nuclear factor-κB, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. Exp Biol Med. 2015;240:411–417. doi:10.1177/1535370214554533
   Web of Science ®Google Scholar